Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-010: Zilovertamab vedotin + R-CHP versus R-CHOP in untreated DLBCL
CTR20244694Phase 3Active
- Sponsor
- MSD
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by MSD. Started Mar 2025; status: active.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20244694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244694.